VSTMVerastem, Inc.Running, no new patients
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
KRAS Activating Mutation · Metastatic Cancer · Pancreas Cancer · Neoplasms Pancreatic · Malignant Neoplasm of Pancreas
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Worry score12
Score over time
- Stage
- Phase 1/2
- Patients
- 40 (planned)
- Started
- Mar 22, 2023
- Main results expected
- Aug 31, 2026
- Fully finished
- Aug 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxel
Measured over: 28 days
To determine the efficacy of the RP2D identified in Part A
Measured over: 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05669482 · record last updated 2025-09-02 · checked 2026-11-09 15:36 UTC